Related Experiment Videos
Chemoprevention by pyrimethamine
Farshid Saadat1, Mohammad Reza Khorramizadeh, Abbas Mirshafiey
1Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Immunopharmacology and Immunotoxicology
|August 24, 2005
Summary
Pyrimethamine, an antimalaria drug, shows chemopreventive potential by suppressing matrix metalloproteinase 2 (MMP-2) activity and inducing apoptosis in fibrosarcoma cells. This suggests its possible use in cancer prevention therapies.
Area of Science:
- Pharmacology
- Cancer Research
- Cell Biology
Background:
- Antimalaria drugs are being explored for novel therapeutic applications beyond infectious diseases.
- Chemoprevention strategies aim to prevent cancer development or recurrence.
- Matrix metalloproteinase 2 (MMP-2) is implicated in tumor progression and metastasis.
Purpose of the Study:
- To evaluate the in vitro chemopreventive potential of pyrimethamine, an antimalaria drug.
- To assess pyrimethamine's effects on cytotoxicity, MMP-2 activity, and apoptosis in fibrosarcoma cells.
Main Methods:
- Utilized the fibrosarcoma (WEHI-164) cell line for in vitro experiments.
- Assessed cytotoxicity and apoptosis using standard cell-based assays (e.g., TUNEL method).
- Quantified matrix metalloproteinase 2 (MMP-2) activity via zymoanalysis.
Main Results:
- Pyrimethamine demonstrated greater tolerability compared to methotrexate across tested concentrations.
- Pyrimethamine exhibited a dose-dependent inhibition of MMP-2 activity, though less potent than methotrexate.
- Pyrimethamine treatment significantly increased apoptosis rates in a dose-dependent manner.
Conclusions:
- Pyrimethamine exhibits chemopreventive properties through MMP-2 suppression and apoptosis induction.
- These findings support the investigation of pyrimethamine as a potential agent for chemoprevention therapy.
- Further research is warranted to explore pyrimethamine's efficacy and safety in preclinical cancer models.